Anti-Human Globulin Anti-IgG (Rabbit)

Does not Contain Antibodies to Complement Components FOR IN-VITRO DIAGNOSTIC USE For Tube Testing MEETS FDA POTENCY REQUIREMENTS U.S. License Number: 1798 Package size [REF] 804175100 [VOL] 10 x 10 mL Anti-Human Globulin Anti-IgG Intended Use Anti-Human Globulin Anti-IgG is used for the direct antiglobulin test to demonstrate the in-vivo coating of red blood cells with antibody molecules (such as autoantibodies, maternal antibodies in hemolytic disease of the newborn, alloantibodies against red cells in transfusion reactions). Anti-Human Globulin Anti-IgG is used for the indirect antiglobulin test to demonstrate the in-vitro coating of red blood cells with antibody molecules as in the detection and identification of unexpected antibodies as well as crossmatch tests. Furthermore, blood group antigen typing (with the corresponding test reagent for the indirect antiglobulin test) can be carried out. Summary Moreschi first described the use of Anti-Human Globulin in 19081 . Coombs rediscovered the test in 1945.2,3 By injecting rabbits with human IgG, they were able to produce a protein (Anti-IgG) that reacted with incomplete antibodies (IgG). Most “incomplete” antibodies (IgG) fail to agglutinate red blood cells suspended in saline.4 Most clinically significant antibodies in red blood cell serology are of the IgG class and can only be detected by the use of Anti-IgG. A stable lattice structure is formed and agglutination occurs when Anti-IgG binds to the IgG sensitized red blood cells. Biotest Anti-Human Globulin reagents are used to test for the presence or absence of unexpected red blood cell antibodies. Furthermore, blood group antigen typing (with the corresponding test reagent for the indirect antiglobulin test) can be carried out. Routine pretransfusion studies always include tests for antibody screening, crossmatch and antibody identification

Copy of FDA